AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02015559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mucoadhesive oral wound rinse
Description: Given PO
Study NCT02015559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01685411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Day -8 (prior to transplant): Per institutional guidelines
Study NCT01685411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keppra
Description: Day -8 (prior to transplant): Per institutional guidelines
Study NCT01685411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Days -7 through -4 (prior to transplant): given intravenously (IV) infusion over 2 hours every 6 hours following dose, administration and pharmacokinetic monitoring per University of Minnesota institutional guidelines.
Study NCT01685411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -3 and -2 (prior to transplantation): given as a 2 hour intravenous infusion with a high volume fluid flush and mesna per institutional guidelines. Dosing is based on actual body weight.
Study NCT01685411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: All patients (regardless of allograft source) will receive tacrolimus therapy beginning on day -3. Dosing will be monitored and altered as clinically appropriate per institutional pharmacy guidelines. Dose adjustments will be made on the basis of toxicity and/or low tacrolimus levels. Taper at day +100 for matched sibling donor (MSD) recipients, and day +180 for non-MSD recipients. Taper to zero by 10% weekly dose reduction over approximately 10 weeks.
Study NCT01685411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Day -3 (prior to transplant): Recipients of umbilical cord blood will given a dose of 3 gm/day every 8 or 12 hours (> or = 40 kg) or 15 mg/kg 3 times per day (\< 40 kg) for up to 30 days unless no engraftment.
Study NCT01685411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplant
Description: Day 0 (or Day+1/+2 to accommodate weekdays): Infusion of cells from related or unrelated donor bone marrow or single or double unrelated donor umbilical cord blood.
Study NCT01685411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Beginning Day +1: Intravenously (IV) 5 mcg/kg once daily and continuing until the absolute neutrophil count is >2500 x 10\^9/L or per institutional guidelines.
Study NCT02920307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TEP without fixation
Description: Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
Study NCT02920307 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEP with fixation
Description: Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
Study NCT02920307 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAPP without fixation
Description: Standard transabdominal preperitoneal (TAPP) inguinal hernia repair without mesh fixation
Study NCT02920307 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAPP with fixation
Description: Standard transabdominal preperitoneal (TAPP) inguinal hernia repair
Study NCT02137447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure treatment
Study NCT01635998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific Vessix Renal Denervation System
Description: Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.~Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts
Study NCT00004891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Study NCT00004891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Study NCT00004891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00004891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT00004891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Study NCT00004891 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radionuclide imaging
Study NCT00004891 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Study NCT00004891 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01654874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-MIP-1404
Study NCT01072448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 75 μg
Description: Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
Study NCT01072448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
Study NCT04361448 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: samling of oropharynx and nasopharynx
Description: Three different swabs will be taken of each participant: 1 oropharyngeal swab and 2 nasopharyngeal swabs
Study NCT02446769 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVAPS-AE Non-invasive ventilation therapy
Description: Participants will use the device greater than or equal to 4hrs per night for the 60 days after discharge.
Study NCT00049322 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV, 10mg/kg evey two weeks starting 1 week prior to the first chemoembolization.~Patients crossed over to the Bevacizumab arm will receive Bevacizumab after week 14 at the same dose.
Study NCT01184677 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insertion of the ProSeal LMA (PLMA)
Description: ProSeal LMA size 3 is inserted to the patients of Group size 3.
Study NCT01184677 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: insertion of the PLMA
Description: ProSeal LMA size 4 is inserted to the patients of Group size 4.
Study NCT04538599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD13-01 cell infusion
Description: Universal CAR-T cells targeting CD7
Study NCT03534505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketorolac group
Description: patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Ketorolac group will receive local infiltration in abdominal sheath layer with Ketorolac 30 mg in normal saline 10ml. And then skin closure will be done by nylon 3-0.
Study NCT03534505 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine group
Description: patients will undergo herniorrhaphy with Lichtenstein Tension-Free Repair technique. After abdominal sheath will be closed by Vicryl No.0, Patients who are the Bupivacaine group will receive local infiltration in abdominal sheath layer with 0.5% bupivacaine 10 ml. And then skin closure will be done by nylon 3-0.
Study NCT01685411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: antithymocyte globulin
Description: Administered per institutional guidelines for recipients of umbilical cord blood transplant.
Study NCT02712333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Air Purifiers
Description: The 17 dormitory rooms and their residents were randomized into two groups: the intervention and control group. The intervention group went through a 9-day intervention with an air purifier placed in the center of the room. All rooms in this group used the same qualified air purifiers (model KJEA200e, 3M), and all participants were required to stay in their dormitory rooms with the windows/doors closed throughout intervention period. All participants and research staffs were blinded to the group assignment.
Study NCT02712333 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Air Purifiers
Description: The control group went through a 9-day intervention with a sham air purifier (with its filter gauze removed) placed in the center of the room. All rooms used the same air purifiers (model KJEA200e, 3M) as the intervention group, except the filter gauze was removed. During the study period all participants were required to stay in their dormitory rooms with the windows/doors closed. All participants and research staffs were blinded to the group assignment.
Study NCT04006483 — intervention group
Intervention type: DRUG
Intervention: Stannous fluoride dentifrice
Description: Stannous fluoride (0.454%) dentifrice
Study NCT04006483 — intervention group
Intervention type: DRUG
Intervention: Positive control dentifrice
Description: Positive control dentifrice containing (0.3%) triclosan.
Study NCT04006483 — intervention group
Intervention type: DRUG
Intervention: Negative control dentifrice
Description: Negative control dentifrice containing either sodium fluoride (0.243%) or sodium monofluorophosphate (0.76%)
Study NCT01884818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manipulation vs. TNS thoracic pain
Study NCT01884818 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Manipulation vs. TNS thoracic pain
Study NCT04172116 — intervention group
Intervention type: DEVICE
Intervention: Continuous glucose monitoring
Description: see arm/group descriptions
Study NCT01283594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tozadenant (SYN115) 60 mg BID
Description: Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 60 mg BID.
Study NCT01283594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: White-coated, modified-oval placebo tablets.
Study NCT02740491 — intervention group
Intervention type: OTHER
Intervention: Remission Consultation
Description: At the end of adjuvant treatment (adjuvant chemotherapy and / or radiotherapy), the patient is seen by a referent oncologist and included in the study. A Remission consultation with a psychotherapist is then proposed and its purpose explained to the patient. The patient agrees or refuses take advantage of the Remission consultation; in case of refusal, the reasons are documented and further information is provided, thus giving the opportunity for the patient to benefit from further psychological counseling if desired.~If approval is given, the patient will be scheduled for the Remission consultation (duration 1 hour) . The latter includes a first phase evaluating the mental state of the patient, and then a proposal of individualized care if necessary and according to several methods, depending on the choice of the patient.
Study NCT03035370 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix™
Description: Four weeks after the second Viaskin application (at Day 42 of the study), all subjects will receive a dose of diphtheria-tetanus-pertussis vaccine (Boostrix® dTpa) to ensure the optimal recall of their immunity against pertussis.
Study NCT03035370 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Boostrix™
Description: Four weeks after the second Viaskin application (at Day 42 of the study), all subjects will receive a dose of diphtheria-tetanus-pertussis vaccine (Boostrix® dTpa) to ensure the optimal recall of their immunity against pertussis.
Study NCT03198247 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The biomedical education session will be imparted 2 weeks before surgery by the preoperative nurse and a physiotherapist. It will have a duration of 2 hours and it is designed for a group of 5 subjects.~The hospital rehabilitation starts 6 hours after surgery, and it is based in early wandering stimulation, articular mobility exercises and isometric exercises.
Study NCT03198247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: The biomedical education session will be imparted 2 weeks before surgery by the preoperative nurse and a physiotherapist. It will have a duration of 2 hours and it is designed for a group of 5 subjects.~The hospital rehabilitation starts 6 hours after surgery, and it is based in early wandering stimulation, articular mobility exercises and isometric exercises.
Study NCT03198247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNE + CST
Description: The PNE and CST program will be divided in 3 individual sessions.
Study NCT01937416 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous bone marrow mononuclear cells
Description: Bone marrow was taken from patient oneself and mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation. Bone marrow mononuclear cells were transplanted into ischemia regions of lower limb through intramuscular injection.
Study NCT00843024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan and Naproxen Sodium
Description: Sumatriptan succinate and naproxen sodium
Study NCT01283594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levodopa (L-dopa)
Description: One intravenous infusion of L-dopa to reach approximately 600 ng/ ml plasma concentration.
Study NCT01283594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa (L-dopa)
Description: One intravenous infusion of L-dopa to reach approximately 600 ng/ ml plasma concentration.
Study NCT01283594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tozadenant (SYN115) 120 mg BID
Description: Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 120 mg BID.
Study NCT00843024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match
Study NCT01283594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tozadenant (SYN115) 180 mg BID
Description: Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 180 mg BID.
Study NCT01283594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tozadenant (SYN115) 240 mg BID
Description: Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.~Total daily doses include 240 mg BID.
Study NCT02397408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon C 11 Choline
Description: Given intravenously (IV) prior to imaging
Study NCT02397408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Choline
Description: Given intravenously (IV) prior to imaging
Study NCT02397408 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET) / Magnetic Resonance Imaging (MRI)
Description: Undergo whole-body PET/MR imaging
Study NCT02277145 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: clinical grade umbilical cord mesenchymal stem cells
Description: 10\^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after fully lavage of the localized lesions
Study NCT01741597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Undergo DCE-MRI
Study NCT02151903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DI-Leu16-IL2
Description: DI-Leu16-IL2 will be administered per dose and schedule specified in the arm.
Study NCT02195453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yangzhengxiaoji Capsule
Description: Gemcitabine 1000mg/m² or Pemetrexed 500mg/m² IV drip on D1 and D8,21 days for a cycle.~Cisplatin 75mg/m² IV drip for one day or two-three days total injection,21 days for a cycle.~Yangzhengxiaoji Capsule four granules t.i.d po.
Study NCT02195453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: Gemcitabine 1000mg/m² or Pemetrexed 500mg/m²IV drip on D1 and D8,21 days for a cycle.~Cisplatin 75mg/m² IV drip for one day or two-three days total injection, 21 days for a cycle.~Placebo Capsule four granules t.i.d po.
Study NCT04029311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nuance Pro
Description: Study compares Nuance Pro plus Automatic Positive Airway Pressure (autoPAP) vs TAP PAP plus autoPAP
Study NCT01741597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT04029311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autoPAP
Description: autoPAP
Study NCT04257409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical intervention by exercise
Description: 12 week lasting exercise intervention
Study NCT01741597 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tumor-homing peptide iRGD
Description: Undergo tumor-homing peptide iRGD DCE-MRI
Study NCT04029311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAP PAP
Description: TAP PAP
Study NCT04119921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prescription topical ketorolac in group 1
Description: topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
Study NCT04119921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prescription artificial tear in group 2
Description: artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
Study NCT04119921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prescription topical ketorolac in group 2
Description: artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
Study NCT04119921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prescription artificial tear in group1
Description: topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
Study NCT03265769 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: radial access site
Description: radial route
Study NCT04142892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onapristone
Description: 50 mg given orally (PO), twice a day (BID), in a continuous schedule (QD) during 3 weeks (+/-3 days)
Study NCT01080664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS703569
Description: Dose Escalation~Regimen 1 - 3-47 mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion~Regimen 1 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops
Study NCT01080664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS703569
Description: Dose Escalation Regimen 2 - 3-47 mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion Regimen 2 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops.
Study NCT03265769 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: femoral access site
Description: femoral route
Study NCT01763983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: CBT will be delivered individually, 1 hour per week, for 12 consecutive weeks. CBT for stress in MS is a structured, short-term, present-oriented therapy with an emphasis on problem-solving and the modification of dysfunctional thinking and behaving. Cognitive strategies include the use of dysfunctional thought records for recording and challenging negative automatic thoughts and the use of behavioural strategies to increase involvement and commitment to personal goals.~Group therapy following a similar protocol (2 hrs/week) will be offered to those in the waitlist condition after completing the study.
Study NCT04491903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: REBOA
Description: Endovascular balloon occlusion of the aorta
Study NCT03136653 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MP0250 plus BOR+DEX
Description: 6 mg/kg or 8 mg/kg or 12 mg/kg of MP0250, IV (in the vein,) on day 1 of each 21 day cycle. Bortezomib and Dexamethasone according to label.~Number of Cycles: until progression or unacceptable toxicity develops.
Study NCT03397771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Litoxetine
Description: oral study medication provided in a dose titration manner
Study NCT03397771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo medication provided in a dose titration manner
Study NCT01340326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dose of valsartan
Description: comparison of different dosages of drug
Study NCT01340326 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: usual dose of valsartan
Description: comparison of different dosages of drug